INMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
INMED PHARMACEUTICALS INC. (INM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 138.15 thousand shares for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 0.00 shares.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 0.00 shares.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 61.72K shares, a 98.07% increase from fiscal 2022.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 31.16K shares, a 91.37% decline from fiscal 2021.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 361.25K shares, a 585.12% increase from fiscal 2020.
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 52.73K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | 0.00 shares derived: sum of 2 quarters · filed 2026-09-09 | 138.15K shares S-4/A · filed 2026-09-09 | ||
| 2026-03-31 | 0.00 shares derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | 138.15K shares S-4 · filed 2026-07-02 | |||
| 2025-12-31 | 138.15K shares 10-Q · filed 2026-02-11 | ||||
| 2025-06-30 | 0.00 shares derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-09 | 0.00 shares derived: sum of 2 quarters · filed 2026-09-09 | 28.70K shares S-4/A · filed 2026-09-09 | ||
| 2025-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | 28.70K shares 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | 28.70K shares 10-Q · filed 2025-02-12 | ||||
| 2024-06-30 | 29.02K shares S-4 · filed 2026-07-02 | 580.40K shares 10-K · filed 2024-09-30 | |||
| 2023-12-31 | 530.40K shares 10-Q · filed 2024-02-13 | ||||
| 2023-06-30 | 61.72K shares 10-K · filed 2024-09-30 | ||||
| 2022-06-30 | 31.16K shares 10-K · filed 2023-09-29 | ||||
| 2021-06-30 | 22.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | 22.00K shares derived: sum of 2 quarters · filed 2021-09-24 | 361.25K shares 10-K · filed 2021-09-24 | ||
| 2021-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-13 | 339.25K shares 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 339.25K shares 10-Q · filed 2021-02-11 | ||||
| 2020-06-30 | 52.73K shares 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |